Statins in heart failure - Where do we stand?

Cardiovascular Drugs and Therapy

Volumn 25, Issue 1, 2011, Pages 99-104

  Lyons, Kristopher S ^a   McVeigh, Gary E ^a   Harbinson, Mark T ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Atorvastatin; Co enzyme Q10; Heart failure; Rosuvastatin; Simvastatin; Statins

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; UBIDECARENONE;

CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

EID: 79959930804     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6269-1     Document Type: Review

References (47)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet. 2002;360:7-22.
3. Pedersen TR, Faergeman O, Kastelein JJP, et al. High dose atorvastatin vrs usual dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45. (Pubitemid 41627921)
4. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086-92.
5. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105-11. (Pubitemid 44664705)
6. Horwich T, MacLellan W, Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-8. (Pubitemid 38229538)
7. Segal R, Pitt B, Pode-Wilson P, on behalf of the ELITE II, et al. Effects of HMG-COA reductase inhibitors (statins) in patients with heart failure [abstract]. Eur J Heart Fail. 2000;2:96.
8. Perreault S, Dragomir A, Blais L, et al. Impact of adherence to statins on chronic heart failure in primary prevention. Brit J Clin Pharmacol. 2008;66:706-16.
9. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249-54. (Pubitemid 127674856)
10. Strey CH, Young JH, Lainchbury JH, et al. Short term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart. 2006;92:1603-9. (Pubitemid 44629164)
11. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546-9. (Pubitemid 34123425)
12. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-35. (Pubitemid 28152885)
13. Bucci M, Gratton JP, Rudic RD, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000;6:1362-7. (Pubitemid 32001020)
14. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-271.
15. Hamilton PK, Hughes SMT, Plumb RD, et al. Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia. Clin Sci. 2010;118:359-66.
16. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus Ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-63. (Pubitemid 40647072)
17. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-9. (Pubitemid 39331904)
18. Yin W, Chen J, Jen H, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931-8. (Pubitemid 38881011)
19. Sola S, Mir MQS, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. JACC. 2006;47:332-7. (Pubitemid 43063250)
20. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839-43. (Pubitemid 37022126)
21. The Corona Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.
22. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo controlled trial. Lancet. 2008;372:1231-9.
23. Lipinski MJ, Cauthen CA, Biondi-Zoccai GGL, et al. Metaanalysis of randomized controlled trials of statins vrs placebo in patients with heart failure. Am J Cardiol. 2009;104:1708-16.
24. Masoudi FA. Statins for ischaemic systolic heart failure. N Engl J Med. 2007;357:2301.
25. Laufs U, Custodis F, Bohm M. Who does not need a statin? Too late in end-stage renal disease and heart failure? Heart. 2008;94:1138-40.
26. Cleland JGF, McMurray JJV, Kjekshus J, on behalf of the CORONA Study Group, et al. Plasma concentration of aminoterminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850-9.
27. Vredevoe DL, Woo MA, Doering LV, et al. Skin test anergy in advanced heart failure secondary to either ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82:323-8. (Pubitemid 28364248)
28. Horwich TB, Hamilton MA, MacLellan WR, et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216-24.
29. Rauchhaus M, Clark A, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933-40. (Pubitemid 37485568)
30. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106:2041-2. (Pubitemid 35192806)
31. Kucharská J, Gvozdjáková A, Šimko F. Simvastatin decreased CoQ in the left ventricle and skeletal muscle, but not in the brain and liver in L-NAME-induced hypertension. Physio Res. 2007;56: S49-54.
32. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum Ubiquinol-10 levels by atoravastatin in hypercholesterolaemic patients. J Atheroscler Thromb. 2005;12:111-9.
33. Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:1435-41.
34. Florkowski CM, Molyneux SL, George PM. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2008;358:1301. (Pubitemid 351439240)
35. McMurray JJV, Dunselman P, Wedel H, et al. Coenzyme Q10, rosuvastatin and clinical outcomes in heart failure. J Am Coll Cardiol. 2010;56:1196-204.
36. Keith M, Mazer CD, Mikhail P, et al. Co-enzyme Q10 in patients undergoing CABG: effect of statins and nutritional supplementation. Nutr Metab Cardiovasc Dis. 2008;18:105-11. (Pubitemid 351282469)
37. Kuettner A, Pieper A, Koch J, et al. Influence of coenzyme Q10 and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study. Int J Cardiol. 2005;98:413-9. (Pubitemid 40247930)
38. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464-72. (Pubitemid 46106977)
39. Shin MJ, Chung N, Lee JH, et al. Effect of simvastatin on plasma antioxidant status and vitamins in hypercholesterolaemic patients. Int J Cardiol. 2007;118:173-7. (Pubitemid 46601646)
40. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"-A multinational trial. Biofactors. 2003;18:79-89. (Pubitemid 38030702)
41. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-60. (Pubitemid 36835963)
42. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003;42:1091-7. (Pubitemid 37108599)
43. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharm. 2001;133:406-12. (Pubitemid 33027777)
44. The Jupiter study group. Rosuvastatin to prevent vascular events in men and women with elevated CRP. N Engl J Med. 2008;359:2195-207.
45. ESC taskforce. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Health J. 2008;29:2388-442.
46. NICE Guideline Chronic Heart Failure. Management of chronic heart failure in adults in primary and secondary care. July 2003.
47. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94:1306-10. (Pubitemid 39469957)